Form 4: Jazz Pharmaceuticals Director Sells Shares

Jazz Pharmaceuticals Director Bruce C. Cozadd reported the sale of ordinary shares valued at approximately $190 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Bruce C. Cozadd, a Director at Jazz Pharmaceuticals plc, has reported the sale of ordinary shares.
• The transactions were executed on April 1, 2026, under a Rule 10b5-1 trading plan adopted on November 26, 2025.
• Sales occurred at weighted average prices of $190.222, $190.9383, and $191.7447.
• The total number of shares sold across these transactions is 6,010.
• Following these sales, Mr. Cozadd beneficially owns 384,682 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sales were conducted under a pre-arranged 10b5-1 plan, indicating they were not discretionary and likely part of a pre-planned financial strategy.

Negatives

• Director Bruce C. Cozadd sold a significant number of ordinary shares (6,010) in the company.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Management Comments

• The transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
• The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Industry Context

StockSavvy.ai notes that insider sales, particularly when executed under a 10b5-1 plan, are common and often reflect personal financial planning rather than a negative view of the company's prospects. However, significant sales by directors can sometimes be interpreted by the market as a signal, regardless of the plan's nature.

Stakeholder Impact

• Shareholders may note the sale of shares by a director, though the 10b5-1 plan context mitigates concerns about insider knowledge.
• The company's management team continues to operate under established trading policies.

Key Dates

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, Insider Trading, Share Sale, Bruce C. Cozadd, 10b5-1 plan, Director, Beneficial Ownership